Nanoscope Therapeutics Advances Optogenetic Therapy with Rolling BLA Submission and Expansion Plans
核心洞察
Nanoscope Therapeutics (搜索) has initiated a rolling Biologics License Application (BLA) with the FDA for MCO-010, its optogenetic therapy for retinitis pigmentosa (搜索), following positive Phase 2b/3 trial results.
The REMAIN study demonstrated durable and clinically meaningful vision improvements three years after a single intravitreal injection of MCO-010 in retinitis pigmentosa (搜索) patients.
The company plans to expand its disease-agnostic MCO platform into geographic atrophy (搜索) and initiate a Phase 3 trial for Stargardt disease (搜索) in early 2026.
Nanoscope Therapeutics (搜索) has initiated a rolling Biologics License Application (BLA) with the U.S. Food and Drug Administration for MCO-010, its lead optogenetic therapy for retinitis pigmentosa (搜索) (RP), marking a significant regulatory milestone for the biotechnology company's vision-restoring treatment platform.
The Dallas-based company announced that CEO Sulagna Bhattacharya will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, highlighting the company's regulatory progress and clinical momentum. The presentation will focus on the recently reported three-year follow-up results from the REMAIN study, which demonstrated durable and clinically meaningful vision improvements following a single intravitreal injection of MCO-010.
Clinical Progress Across Multiple Indications
The rolling BLA submission follows positive results from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial for retinitis pigmentosa (搜索). If approved, MCO-010 has the potential to become the standard of care for RP patients, administered as a one-time, in-office injection without the need for genetic testing.
Beyond retinitis pigmentosa (搜索), Nanoscope has demonstrated promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (搜索) (SD). The company plans to initiate a Phase 3 registrational trial for Stargardt disease in early 2026, expanding the therapeutic potential of its multi-characteristic opsin (MCO) platform.
Disease-Agnostic Platform Expansion
The company's MCO platform represents a disease-agnostic therapy designed to restore vision in patients with photoreceptor (搜索) degeneration. The platform works by activating highly dense bipolar retinal cells (搜索) to become light sensitive, utilizing the remaining visual circuitry following photoreceptor death.
Nanoscope plans to expand into geographic atrophy (搜索) (GA) with a Phase 2 program expected to start in early 2026. This expansion supports the disease-agnostic potential of the MCO platform for potentially millions of patients worldwide with severe vision loss due to photoreceptor (搜索) death.
Regulatory Recognition and Future Pipeline
MCO-010 has received significant regulatory recognition, including FDA Fast Track and Orphan Drug designations for both RP and SD, along with Regenerative Medicine Advanced Therapy (RMAT) designation for SD. The European Medicines Agency has granted Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies.
The company's pipeline includes other IND-ready programs for Leber congenital amaurosis (搜索) (LCA), further demonstrating the broad applicability of the optogenetic approach across retinal degenerative diseases.
"With our rolling BLA underway, and important milestones across RP, Stargardt disease (搜索), and GA ahead, 2026 is a critical year for Nanoscope and an exciting time to partner with investors who share our mission to help patients, who have been left without treatment options, gain meaningful vision," said Bhattacharya.
The MCO treatment approach offers several advantages over existing therapies, requiring no genetic testing, invasive surgery, or repeat dosing, enabling broad patient applicability within existing retina office workflows.